Trinity Biotech
TRIB
47 hedge funds and large institutions have $76M invested in Trinity Biotech in 2017 Q4 according to their latest regulatory filings, with 6 funds opening new positions, 9 increasing their positions, 15 reducing their positions, and 11 closing their positions.
27% more capital inflows, than outflows
Capital inflows: $8.59M | Capital outflows: $6.79M
1.92% more ownership
Funds ownership: 69.49% → 71.41% (+1.9%)
10% less funds holding
Funds holding: 52 → 47 (-5)
40% less repeat investments, than reductions
Existing positions increased: 9 | Existing positions reduced: 15
45% less first-time investments, than exits
New positions opened: 6 | Existing positions closed: 11
50% less funds holding in top 10
Funds holding in top 10: 2 → 1 (-1)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Russell Investments Group
London,
United Kingdom
|
+$3.42M |
| 2 |
Morgan Stanley
New York
|
+$1.58M |
| 3 |
Renaissance Technologies
New York
|
+$621K |
| 4 |
Senvest Management
New York
|
+$575K |
| 5 |
State Street
Boston,
Massachusetts
|
+$543K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Parametric Portfolio Associates
Seattle,
Washington
|
-$1.29M |
| 2 |
Boston Partners
Boston,
Massachusetts
|
-$880K |
| 3 |
Stonepine Capital Management
Bend,
Oregon
|
-$688K |
| 4 |
D.E. Shaw & Co
New York
|
-$613K |
| 5 |
Lapides Asset Management
Greenwich,
Connecticut
|
-$599K |
TRIB Hedge Fund Activity: Q4 2017 in Review
47 of the 4,420 institutional investors tracked by Wall St. Rank reported a position in Trinity Biotech (TRIB) for Q4 2017, worth a combined $76M — down 6.7% from $81.5M a quarter earlier.
Sellers outnumbered buyers: 11 funds closed out of TRIB and 6 opened new positions — a net loss of 5 holders — while 15 trimmed existing stakes and 9 added.
The largest buyer was Russell Investments Group, adding an estimated $3.42M. The largest seller was Parametric Portfolio Associates, exiting entirely with an estimated $1.29M sold.
- 47 institutional investors held Trinity Biotech (TRIB) as of Q4 2017, down from 52 in Q3 2017.
- Funds reported $76M of Trinity Biotech stock for Q4 2017, down 6.7% quarter-over-quarter.
- 6 funds opened new Trinity Biotech positions in Q4 2017 and 11 closed out, a net change of -5 holders.
- The largest Trinity Biotech buyer in Q4 2017 was Russell Investments Group, an estimated $3.42M added.
- The largest Trinity Biotech seller in Q4 2017 was Parametric Portfolio Associates, an estimated $1.29M sold.
Based on aggregated 13F filings for Q4 2017.